

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
7 October 2004 (07.10.2004)

PCT

(10) International Publication Number
WO 2004/084898 A1

(51) International Patent Classification⁷: **A61K 31/4965, 31/439, 31/4015, 31/405, 31/497, C07C 311/37, C07D 241/04, 453/02, 207/40, 403/06, 487/04, 401/04, 243/08, 403/04, 207/34**

(21) International Application Number:
PCT/EP2004/002496

(22) International Filing Date: 11 March 2004 (11.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03006293.9 24 March 2003 (24.03.2003) EP

(71) Applicant (for all designated States except US): **BAYER HEALTHCARE AG [DE/DE]; 51368 Leverkusen (DE).**


(72) Inventors; and

(75) Inventors/Applicants (for US only): **LI, Yingfu [CN/JP];**

4-260-1-509, Omiya-cho, Nara-shi, Nara 630-8115 (JP). BACON, Kevin [GB/JP]; 5-15-912, Koyo-cho, Higashinada-ku, Kobe-shi, Hyogo 658-0032 (JP). SUGIMOTO, Hiromi [JP/JP]; 4-25-2-B201, Sakuragaoka, Seika-cho, Soraku-gun, Kyoto 619-0232 (JP). FUKUSHIMA, Keiko [JP/JP]; D-201 3-5-17, Sakyō, Nara-shi, Nara 631-0801 (JP). HASHIMOTO, Kentaro [JP/JP]; 8-5-106, Higashi-machi, Minamihanda, Nara-shi, Nara 630-8277 (JP). MARUMO, Makiko [JP/JP]; 4-9-307, Minami-machi, Saidaiji, Nara-shi, Nara 631-0824 (JP). MORIWAKI, Toshiya [JP/JP]; 2-25-4, Kitayamato, Ikoma-shi, Nara 630-0121 (JP). NUNAMI, Noriko [JP/JP]; D-201 3-5-14, Sakyō, Nara-shi, Nara 631-0801 (JP). TSUNO, Naoki [JP/JP]; 135-1-102, Aono-cho, Nara-shi, Nara 631-0841 (JP). URBAHNS, Klaus [DE/JP]; 6-3-1-301, Kusugaoka-cho, Nada-ku, Kobe-shi, Hyogo 657-0024 (JP). YOSHIDA, Nagahiro [JP/JP]; 5-18-15, Saganakadai, Kizu-cho, Soraku-gun, Kyoto 619-0223 (JP).

[Continued on next page]

(54) Title: **2-PHOXY- AND 2-PHENYLSULFOMAMIDE DERIVATIVES WITH CCR3 ANTAGONISTIC ACTIVITY FOR THE TREATMENT OF ASTHMA AND OTHER INFLAMMATORY OR IMMUNOLOGICAL DISORDERS**



(57) Abstract: The present invention relates to a benzenesulfonamide derivative of formula (I), which is useful as an active ingredient of pharmaceutical preparations. The benzenesulfonamide derivatives of the present invention have CCR3 (CC type chemokine receptor) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with CCR3 activity, in particular for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders. In said formula, X represents O or S; R⁴ represents formulae (a), (b), (c), (d), (e), (f), (g), (h), (i) or (j), the other substituents are as defined in claim 1.

WO 2004/084898 A1



(74) Common Representative: BAYER HEALTHCARE AG; Law & Patents, Patents and Licensing, 51368 Leverkusen (DE).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH,

GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.